Showing results (451-460 of 478) with videos related to

Sort By:
Pageof 48
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Annals of Internal Medicine|October 6, 2010
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patientsSteven Rosenberg, Michael R Elashoff, Philip Beineke, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
JAMA|May 12, 2005
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trialHakon Hakonarson, Sverrir Thorvaldsson, Anna Helgadottir, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 16, 2007
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery diseaseMay M Luke, John P Kane, Dongming M Liu, et al.
JACC. Cardiovascular Interventions|October 24, 2009
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trialStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 22, 2015
Prediction of Causal Candidate Genes in Coronary Artery Disease LociIngrid Brænne, Mete Civelek, Baiba Vilne, et al.
JAMA|March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialMatthew J Price, Peter B Berger, Paul S Teirstein, et al.
European Heart Journal|March 28, 2012
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt, Guillaume Paré, John W Eikelboom, et al.
NPJ Digital Medicine|March 12, 2022
Impact of polygenic risk communication: an observational mobile application-based coronary artery disease studyEvan D Muse, Shang-Fu Chen, Shuchen Liu, et al.
Pageof 48